Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | MELK | Q14680 | 1/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12035274 | 0.90 | NPC1 (0.52) | JAK3MELKHSD17B1HSD17B2BRAF | |
| SCHEMBL4361312 | 0.89 | DYRK1A (0.50) | JAK3MELKHSD17B1HSD17B2BRAF | |
| SCHEMBL4352342 | 0.88 | JAK3 (0.47) | JAK3MELKHSD17B1HSD17B2BRAF | |
| SCHEMBL4348258 | 0.88 | MEN1 (0.47) | JAK3TTKMAPK8RAB9ASMN1; SMN2 | |
| SCHEMBL11939374 | 0.87 | FYN (0.62) | JAK3MELKHSD17B1HSD17B2BRAF | |
| SCHEMBL4354392 | 0.87 | TTK (0.49) | JAK3MELKHSD17B1HSD17B2BRAF | |
| SCHEMBL4351868 | 0.87 | PDE5A (0.48) | JAK3MELKHSD17B1HSD17B2BRAF | |
| SCHEMBL4349719 | 0.87 | ABL1 (0.47) | JAK3MELKHSD17B1HSD17B2BRAF | |
| SCHEMBL12035407 | 0.86 | JAK3 (0.46) | JAK3MELKHSD17B1HSD17B2BRAF | |
| SCHEMBL4355415 | 0.86 | TTK (0.48) | JAK3MELKHSD17B1HSD17B2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312992-A1 | Inhibitors of C-Kit and Uses Thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-12-22 | — | — | US | claimed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2471529-A2 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | Emory University (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20110312992-A1 | Inhibitors of C-Kit and Uses Thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-12-22 | — | — | US | disclosed |
| US-20110312992-A1 | Inhibitors of C-Kit and Uses Thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-12-22 | — | — | US | disclosed |
| US-20110312992-A1 | Inhibitors of C-Kit and Uses Thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-12-22 | — | — | US | disclosed |
| EP-2364702-A2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | Emory University (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090281115-A1 | INHIBITORS OF C-KIT AND USES THEREOF | Board of Regents, The University of Texas System, a Texas University (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281115-A1 | INHIBITORS OF C-KIT AND USES THEREOF | Board of Regents, The University of Texas System, a Texas University (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2008005877-A2 | INHIBITORS OF C-KIT AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005877-A2 | INHIBITORS OF C-KIT AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | JAK3 163/4885MELK 277/4885HSD17B1 3978/4885 |
| US-20110312992-A1 | Inhibitors of C-Kit and Uses Thereof | KIT, CHUK, MASTL | JAK3 493/4885MELK 802/4885HSD17B1 4193/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | JAK3 163/4885MELK 277/4885HSD17B1 3978/4885 |
| US-20090281115-A1 | INHIBITORS OF C-KIT AND USES THEREOF | KIT, CHUK, MASTL | JAK3 493/4885MELK 802/4885HSD17B1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.